<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1028-4818</journal-id>
<journal-title><![CDATA[Multimed]]></journal-title>
<abbrev-journal-title><![CDATA[Multimed]]></abbrev-journal-title>
<issn>1028-4818</issn>
<publisher>
<publisher-name><![CDATA[Centro Provincial de Información de Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1028-48182022000500003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Supervivencia de pacientes con cáncer de pulmón de células no pequeñas]]></article-title>
<article-title xml:lang="en"><![CDATA[Survival of patients with non-small cell lung cancer]]></article-title>
<article-title xml:lang="pt"><![CDATA[Sobrevivência de pacientes com câncer de pulmão de células não pequenas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Frómeta Guerra]]></surname>
<given-names><![CDATA[Adonis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Figueredo]]></surname>
<given-names><![CDATA[Sandra Amalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Naranjo Flores]]></surname>
<given-names><![CDATA[Liannys Lidia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fuentes Liens]]></surname>
<given-names><![CDATA[Eduardo Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Granma Hospital General Provincial Carlos Manuel de Céspedes ]]></institution>
<addr-line><![CDATA[Bayamo Granma]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2022</year>
</pub-date>
<volume>26</volume>
<numero>5</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1028-48182022000500003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1028-48182022000500003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1028-48182022000500003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  el cáncer de pulmón tiene elevada incidencia a nivel mundial. En cuanto a mortalidad, es la primera localización en ambos sexos, con una tasa de 58,0 por 100 000 y 32,5 por 100 000 en el año 2017 en hombre y mujeres respectivamente.  Objetivos:  identificar los factores relacionados con la supervivencia de los pacientes con cáncer de pulmón de células no pequeñas.  Métodos: se realizó un estudio analítico y observacional de cohorte en pacientes atendidos con el diagnóstico de cáncer de pulmón de células no pequeñas en el servicio de Oncología de del hospital general universitario &#8220;Carlos Manuel de Céspedes&#8221; de Bayamo, Granma, en el período comprendido desde el 1º de enero del 2014 al 31 de diciembre de 2019.  Resultados: el factor más relevante y de carácter independiente fue clasificar en estadio IV al incrementar el riesgo de morir a 1,304 veces (IC: 1,011-2,025; p: 0,000) seguido del estadio IIIB (HR: 1,070; IC: 1,004-2,113; p: 0,000). El modelo de regresión de Cox tiene una capacidad discriminativa adecuada para predecir los pacientes que fallecerán de los que no en pacientes con cáncer de pulmón de células no pequeñas (área: 0,727; IC: 0,516-0,737; p: 0,025).  Conclusiones: el estadio del cáncer de pulmón de células no pequeñas tuvo una relación inversamente proporcional con la sobrevida de los pacientes; la edad avanzada incrementó el riesgo de morir. El modelo de regresión proporcional de Cox tuvo una capacidad discriminativa adecuada para precisar la menor supervivencia de los pacientes con el mencionado diagnóstico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: lung cancer has a high incidence worldwide. In terms of mortality, it is the first location in both sexes, with a rate of 58.0 per 100,000 and 32.5 per 100,000 in 2017 in men and women respectively.  Objectives:  to identify factors related to the survival of patients with non-small cell lung cancer.  Methods:  an analytical and observational cohort study was conducted in patients treated with the diagnosis of non-small cell lung cancer in the Oncology service of the "Carlos Manuel de Céspedes" general university hospital in Bayamo, Granma, in the period from January 1, 2014 to December 31, 2019.  Results:  the most relevant and independent factor was to classify in stage IV by increasing the risk of dying to 1,304 times (CI: 1.011-2.025; p: 0.000) followed by stage IIIB (HR: 1.070; CI: 1.004-2.113; p: 0.000). The Cox regression model has an adequate discriminative capacity to predict patients who will die from those who will not in patients with non-small cell lung cancer (area: 0.727; CI: 0.516-0.737; p: 0.025).  Conclusions:  the stage of non-small cell lung cancer had an inversely proportional relationship with the survival of patients; older age increased the risk of dying. The Cox proportional regression model had an adequate discriminative capacity to specify the shortest survival of patients with the aforementioned diagnosis.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  o câncer de pulmãot em alta incidência em todo o mundo. Em termos de mortalidade, é a primeira localização em ambos os sexos, comum ataxa de 58,0 por 100.000 e 32,5 por 100.000 em 2017 em homens e mulheres, respectivamente.  Objetivos:  identificar fatores relacionados à sobrevivência de pacientes com câncer de pulmão de células não pequenas.  Métodos: estudo de coorte analítica e observacional foi realizado em pacientes tratados com o diagnóstico de câncer de pulmão de células não pequenas no serviço de Oncologia do Hospital Universitário Geral Carlos Manuel de Céspedes, em Bayamo, Granma, no período de 1º de janeiro de 2014 a 31 de dezembro de 2019.  Resultados:  o fator mais relevante e independente foi classificar na fase IV o aumento do risco de morrer para 1.304 vezes (IC: 1.011-2.025; p: 0,000) seguido da etapa IIIB (HR: 1.070; CI: 1.004-2.113; p: 0,000). O modelo de regressão de Cox tem uma capacidade discriminatória adequada para prever pacientes que morrerão daqueles que não morrerão em pacientes com câncer de pulmão de células não pequenas (área: 0,727; CI: 0.516-0.737; p: 0,025).  Conclusões:  o estágio do câncer de pulmão de células não pequenas teve uma relação inversamente proporcional com a sobrevivência dos pacientes; a idade mais velha aumentou o risco de morrer. O modelo de regressão proporcional de Cox apresentou capacidade discriminatória adequada para especificar a menor sobrevida dos pacientes com o diagnóstico acima mencionado.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de pulmón]]></kwd>
<kwd lng="es"><![CDATA[Cáncer de pulmón de células no pequeñas]]></kwd>
<kwd lng="es"><![CDATA[Supervivencia]]></kwd>
<kwd lng="en"><![CDATA[Lung cancer]]></kwd>
<kwd lng="en"><![CDATA[Non-small cell lung cancer]]></kwd>
<kwd lng="en"><![CDATA[Survival]]></kwd>
<kwd lng="pt"><![CDATA[Câncer de pulmão]]></kwd>
<kwd lng="pt"><![CDATA[Câncer de pulmão de células não pequenas]]></kwd>
<kwd lng="pt"><![CDATA[Sobrevivência]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
</person-group>
<source><![CDATA[Ana&#769;lisis de la utilidad de la tomografi&#769;a computarizada volume&#769;trica de to&#769;rax en la evaluacio&#769;n de operabilidad de pacientes con ca&#769;ncer de pulmo&#769;n.]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Autónoma de Madrid]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schabath]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Cote]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer Progress and Priorities: Lung Cancer]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2019</year>
<volume>28</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1563-79</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Qiu]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and survival analyses for occult lung cancer between 2004 and 2015: a population-based study]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2021</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camacho Sosa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso Lemus]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez Rodriguez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Carreño Rolando]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza Jorge]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García Soto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia de pacientes con cáncer de pulmón de células no pequeñas en estadios avanzados. Matanzas]]></article-title>
<source><![CDATA[Revista Médica Electrónica]]></source>
<year>2021</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies an interrupted time series study]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2020</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<collab>Global cancer facts &amp; figures</collab>
<article-title xml:lang=""><![CDATA[Integrative cancer care]]></article-title>
<source><![CDATA[MISKAWAAN]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Torre]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2018</year>
<volume>68</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>394-424</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Schafer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arend]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Armitage]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Clemmons]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Drazen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Goldman's Cecil Medicine]]></source>
<year>2012</year>
<edition>24 ed</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cobian Caballero]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta Brooks]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Feria]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Romero García]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia en pacientes con cáncer pulmonar de células no pequeñas vacunados con CIMAvax-EGF]]></article-title>
<source><![CDATA[Medisan]]></source>
<year>2016</year>
<volume>20</volume>
<numero>03</numero>
<issue>03</issue>
<page-range>320-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>American cáncer society</collab>
<source><![CDATA[Etapas del cáncer de pulmón no microcítico]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Estados Unidos ]]></publisher-loc>
<publisher-name><![CDATA[ACS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Kagiampakis]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Phallen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Patil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[O'Hagan]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations]]></article-title>
<source><![CDATA[Cancer Cell]]></source>
<year>2017</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>360-76</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Martínez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal García]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Montero Martínez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Provencio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ruano Ravina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características al diagnóstico y supervivencia de estadios I y II de cáncer de pulmón]]></article-title>
<source><![CDATA[Arch Bronconeumol]]></source>
<year>2018</year>
<volume>54</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>420-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordova Sanchez]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Ugarte Palacios]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Ugarte Palacios]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Morales Labre]]></surname>
<given-names><![CDATA[KO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de pulmón y su importancia en el diagnóstico primario]]></article-title>
<source><![CDATA[RECIAMUC]]></source>
<year>2022</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>208-17</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Rodríguez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Benavides Márquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez Reyes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gallego Escobar]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Toledo Cabarco]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez Chacón]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El cáncer del pulmón: algunas consideraciones epidemiológicas, del diagnóstico y el tratamiento]]></article-title>
<source><![CDATA[Arch méd Camagüey]]></source>
<year>2018</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>641-52</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrón Barrón]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Guzmán de Alba]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Alatorre Alexander]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aldaco Sarvide]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bautista Aragón]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Blake Cerda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de Práctica Clínica Nacional para el tratamiento del cáncer de pulmón de células no pequeñas en estadios tempranos, localmente avanzados y metastásicos]]></article-title>
<source><![CDATA[Gac Mex Oncol]]></source>
<year>2019</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>201-32</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cervera Deval]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barrios Benito]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Peñalver Cuesta]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Pérez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sandiego Contreras]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz Mojarrieta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cribado de cáncer de pulmón: Supervivencia en un amplio programa de detección precoz en España (I-ELCAP)]]></article-title>
<source><![CDATA[Arch Bronconeumol]]></source>
<year>2022</year>
<volume>58</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>406-11</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Bruges]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carvajal]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Beltrán]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características de los pacientes con cáncer de pulmón de célula no pequeña en el Instituto Nacional de Cancerología de Colombia.]]></article-title>
<source><![CDATA[Rev. Colomb. Cancerol]]></source>
<year>2021</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>103-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cáceres Lavernia]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización del cáncer de pulmón de células no pequeñas con relación al género]]></article-title>
<source><![CDATA[Acta Médica]]></source>
<year>2020</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Ríos]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Cid]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Barrera]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Santillán Doherty]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alatorre Alexander]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Descripción clínico-epidemiológica y molecular del cáncer de pulmón en un centro de referencia nacional]]></article-title>
<source><![CDATA[Neumol Cir Torax]]></source>
<year>2019</year>
<volume>78</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>356-62</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vinageras Neninger]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[López Portugal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cáceres Lavernia]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Varona Rodríguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influencia de enfermedades asociadas en pacientes con cáncer pulmonar no células pequeñas]]></article-title>
<source><![CDATA[Revista Cubana de Oncología]]></source>
<year>2020</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>e-56</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saavedra]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lage]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[T Cell Subpopulations in Healthy Elderly and Lung Cancer Patients: Insights from Cuban Studies]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>146</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
